000127045 001__ 127045 000127045 005__ 20241125101157.0 000127045 0247_ $$2doi$$a10.3390/diagnostics13132220 000127045 0248_ $$2sideral$$a134458 000127045 037__ $$aART-2023-134458 000127045 041__ $$aeng 000127045 100__ $$aBordin, Dmitry S. 000127045 245__ $$aDrug-associated gastropathy: diagnostic criteria 000127045 260__ $$c2023 000127045 5060_ $$aAccess copy available to the general public$$fUnrestricted 000127045 5203_ $$aDrugs are widely used to treat different diseases in modern medicine, but they are often associated with adverse events. Those located in the gastrointestinal tract are common and often mild, but they can be serious or life-threatening and determine the continuation of treatment. The stomach is often affected not only by drugs taken orally but also by those administered parenterally. Here, we review the mechanisms of damage, risk factors and specific endoscopic, histopathological and clinical features of those drugs more often involved in gastric damage, namely NSAIDs, aspirin, anticoagulants, glucocorticosteroids, anticancer drugs, oral iron preparations and proton pump inhibitors. NSAID- and aspirin-associated forms of gastric damage are widely studied and have specific features, although they are often hidden by the coexistence of Helicobacter pylori infection. However, the damaging effect of anticoagulants and corticosteroids or oral iron therapy on the gastric mucosa is controversial. At the same time, the increased use of new antineoplastic drugs, such as checkpoint inhibitors, has opened up a new area of gastrointestinal damage that will be seen more frequently in the near future. We conclude that there is a need to expand and understand drug-induced gastrointestinal damage to prevent and recognize drug-associated gastropathy in a timely manner. 000127045 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000127045 590__ $$a3.0$$b2023 000127045 592__ $$a0.667$$b2023 000127045 591__ $$aMEDICINE, GENERAL & INTERNAL$$b59 / 329 = 0.179$$c2023$$dQ1$$eT1 000127045 593__ $$aClinical Biochemistry$$c2023$$dQ2 000127045 594__ $$a4.7$$b2023 000127045 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion 000127045 700__ $$aLivzan, Maria A. 000127045 700__ $$aGaus, Olga V. 000127045 700__ $$aMozgovoi, Sergei I. 000127045 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, Angel$$uUniversidad de Zaragoza 000127045 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000127045 773__ $$g13, 13 (2023), 2220 [19 pp.]$$tDiagnostics$$x2075-4418 000127045 8564_ $$s8219941$$uhttps://zaguan.unizar.es/record/127045/files/texto_completo.pdf$$yVersión publicada 000127045 8564_ $$s2592746$$uhttps://zaguan.unizar.es/record/127045/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000127045 909CO $$ooai:zaguan.unizar.es:127045$$particulos$$pdriver 000127045 951__ $$a2024-11-22-12:10:02 000127045 980__ $$aARTICLE